CAS: 1196070-26-4

Fiboflapon sodium is a selective leukotriene B4 receptor antagonist, which is a synthetic compound designed to inhibit specific pathways involved in inflammatory processes. The source of Fiboflapon sodium derives from advanced chemical synthesis aimed at targeting the lipoxygenase pathway, crucial in the production of leukotrienes. Its mode of action involves binding to and blocking the leukotriene B4 receptor, thereby reducing the recruitment and activation of inflammatory cells, particularly neutrophils, in response to pro-inflammatory stimuli. The uses and applications of Fiboflapon sodium are primarily centered around its potential therapeutic effects in treating conditions associated with excessive inflammation. Its capacity to mitigate inflammatory responses makes it a candidate for further research in diseases such as asthma, chronic obstructive pulmonary disease (COPD), and potentially other inflammatory disorders where leukotriene pathways play a significant role. Current studies focus on understanding its efficacy, safety profile, and optimal dosing strategies to maximize therapeutic outcomes while minimizing potential side effects.

Fiboflapon sodium, an oral 5-LOX-activating protein inhibitor, binds FLAP at 2.9 nM, inhibits LTB4 at 76 nM.